PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC

Summary

The goal of this clinical trial is to evaluate the clinical value of ctDNA testing in guiding the optimization of immunochemotherapy cycles during induction treatment for resectable patients with NSCLC. The main questions it aims to answer are: * Does ctDNA clearance indicate pathological complete response? * Are additional cycles of immunochemotherapy necessary for patients who have ctDNA clearance after initial cycles of treatment? Researchers will use ctDNA dynamics to guide the cycles of induction treatment to see if some patients can avoid excessive cycles of treatment.

Timeline

Start

2025-05-10

Primary completion

2028-05-10

Completion

2030-05-10

Drugs

Indications